Quantification of Proinsulin in Human Plasma by Proteolysis-Aided Peptide Immunoaffinity-Liquid Chromatography-Tandem Mass Spectrometry
BACKGROUND: Plasma proinsulin concentrations are used to investigate hypoglycemia. They have also been proposed as a marker of β-cell function, particularly as a ratio with C-peptide. Immunoassays remain the primary method for measuring proinsulin despite potential limitations. Mass spectrometry-based assays have been described, but are semiquantitative or rely on nano-flow liquid chromatography. We aimed to develop a liquid chromatography-tandem mass spectrometry assay (LC-MS/MS) at typical clinical laboratory flow rates to quantify proinsulin and its partially processed forms in human plasma and ensure accuracy over time with distributable well-characterized calibrators. METHODS: Sample preparation consists of protein precipitation, Glu-C digestion, peptide immunoaffinity enrichment, and LC-MS/MS analysis of 2 surrogate peptides: RGFFYTPKTRREAE spans the cleavage site for des-31,32-proinsulin and GSLQKRGIVE spans the site for des-64,65-proinsulin. A purified protein calibration material was characterized (HPLC and amino acid analysis) and used to value-assign a matrix-matched single-point calibration material. RESULTS: Within-batch and between-batch imprecision were ≤12.2% and ≤16.4%, respectively. The assay was linear from 0.14 to 53.5 pM and 1.1 to 91.6 pM, with a lower limit of the measuring interval of 2.8 and 8.8 pM for RGFFYTPKTRREAE and GSLQKRGIVE, respectively. The concentration of des-31,32-proinsulin increased more during childhood than intact proinsulin. Participants with type 1 diabetes-associated autoantibodies had higher proinsulin-to-C-peptide ratios. Method comparison with 2 commercial immunoassays revealed variable cross-reactivity with insulin. CONCLUSION: The validated assay is robust and will be a useful tool for advancing studies of β-cell function. A detailed standard operating procedure, well-characterized calibration material, and monoclonal antibodies are available for adoption in other laboratories.
Authors
- Jessica O. Becker
- Andrew N. Hoofnagle (ORCID: https://orcid.org/0000-0002-6449-0243)
- Cate Speake (ORCID: https://orcid.org/0000-0003-1480-4272)
- Elisha Goonatilleke
- Huu‐Hien Huynh (ORCID: https://orcid.org/0000-0002-7814-3189)
- Lili Barahona‐Carrillo
- Sara K Shijo
- Cecilia S. Lee
- Lisa Johnson
- Katrina Forrest
- Michael J MacCoss
Institutions
- Seattle Children's Hospital (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Kidney Research UK (GB)
- Society of Interventional Radiology (US)
Publication Details
- Journal
- Clinical Chemistry
- Published
- 2026-08-21
- DOI
- https://doi.org/10.1093/clinchem/hvag105
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- NHS Innovation Accelerator
- Norges Idrettshøgskole
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- Eunice Kennedy Shriver National Institute of Child Health and Human Development